Cat. No. 3389
No more than 1 g per individual per year to be sold without prior permission from the license holder.
Alternative Names: Casodex, ICI 176,334
Chemical Name: N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
Biological ActivityOrally active non-steroidal androgen receptor antagonist (IC50 = 190 nM). Displays peripheral selectivity and does not effect serum levels of LH and testosterone. Exhibits potent anticancer activity in vivo.
Licensing InformationSold for research purposes only under agreement from AstraZeneca
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Furr et al (1987) ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen. J.Endocrinol. 113 R7. PMID: 3625091.
Tucker et al (1988) Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. J.Med.Chem. 31 954. PMID: 3361581.
Furr and Tucker (1996) The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 47 13. PMID: 8560673.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Bicalutamide, supplier, Non-steroidal, Androgen, receptor, antagonists, Dihydrotestosterone, Receptors, AstraZeneca, ICI176,334
Find multiple products by catalog number
New Products in this Area
Synthetic progesterone analogGC 1
High affinity thyroid receptor α (TRα) and TRβ agonist; thyromimeticSR 8278
Constitutive androstane receptor (CAR) agonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.